U.S. CDMO expansion is increasingly focused on specialized manufacturing capacity rather than generic facility growth.
Sterile fill–finish, lyophilization, injectable packaging, and drug–device combination capabilities represent a major area of recent CDMO investment.
CDMOs are also expanding capacity for ADCs, peptides, API manufacturing, spray drying, complex OSD products, and biologics drug substance.
Sponsors should evaluate CDMO partners based on technical fit, not only available capacity.
A More Specialized Capacity Buildout
Recent U.S. expansion announcements from contract development and manufacturing organizations (CDMOs) point to a capacity buildout that is becoming more specialized, more technically segmented, and more closely tied to the manufacturing requirements of complex products. The most important pattern is not simply that companies are adding facilities, lines, suites, or equipment. It is that many of those investments are aimed at specific categories of need: sterile fill–finish, lyophilization, isolator-based filling, antibody–drug conjugates (ADCs), bioconjugation, peptides, active pharmaceutical ingredient (API) manufacturing, spray drying, biologics drug substance, analytical stability capacity, and drug–device combination products.
That distinction matters because “capacity” can obscure as much as it reveals. A sterile filling line, a 2,000-L single-use biologics manufacturing expansion, a peptide API suite, a spray-drying facility, an analytical stability buildout, and an acquired commercial injectable site all increase capacity, but they do not solve the same problem. Each requires different infrastructure, process knowledge, quality systems, staffing models, validation strategies, and customer fit. For pharma and biopharma companies, the question is not only whether capacity exists but whether the right kind of capacity exists for a given product’s technical and regulatory pathway.
Sterile injectables and fill–finish represented the most visible cluster in the announcements reviewed. Piramal Pharma Solutions broke ground on a $90 million expansion in Lexington, Kentucky, that includes 24,000 additional square feet of manufacturing space, a new filling line, two commercial-size lyophilizers, a specialized capping machine, and an external vial washer.1 Simtra BioPharma Solutions announced the purchase of a 65-acre property in Bloomington, Indiana, with more than 300,000 square feet available for expansion of injectable medicines manufacturing. Thermo Fisher Scientific completed the acquisition of Sanofi’s sterile fill–finish and packaging site in Ridgefield, New Jersey, bringing the site into its pharma services business.
2
3
Other investments targeted different technical challenges. Veranova announced a Devens, Massachusetts, expansion for potent compounds, ADC linker–payloads, and other complex molecules, including a 9,000-ft2 addition with a process development laboratory and two current good manufacturing practice (cGMP) suites.4 Cambrex announced an expansion of Snapdragon Chemistry’s Waltham, Massachusetts, facility to support peptide API development and manufacturing, including a GMP suite, ISO-7 cleanroom, preparative high performance liquid chromatography (HPLC), lyophilization, and storage.5 Hovione completed an initial $100 million investment cycle at its East Windsor, New Jersey, site, including a 31,000-ft2 building with two PSD-3 spray dryers for amorphous solid dispersions (ASDs).6 Bora Biologics opened a $30 million San Diego expansion adding upstream and downstream GMP processing capabilities for 2,000-L single-use biologics manufacturing.7
These announcements depict a CDMO market in which differentiation increasingly depends on fit-for-purpose capabilities. Scale remains important, but scale alone is not enough when products require specialized containment, aseptic processing, conjugation chemistry, peptide purification, spray drying, biologics process control, or device-linked drug product presentation. The capacity question is becoming more precise: not just how much but what kind, where, for which products, and at what stage of development or commercialization.
Why Sterile Fill–Finish Is the Clearest Expansion Cluster
Sterile fill–finish stands out because injectable drug product manufacturing is one of the clearest examples of capacity that cannot be treated as interchangeable. It depends on aseptic processing environments, contamination control, validated filling technologies, trained operators, robust quality systems, and, in many cases, lyophilization, isolator-based operations, injectable packaging, or device-adjacent capabilities. The difference between available manufacturing space and qualified sterile drug product capacity is substantial.
Piramal’s Lexington expansion illustrates the specificity of this type of investment. The project adds manufacturing space, a filling line, two commercial-scale lyophilizers, a specialized capping machine, and an external vial washer, with completion expected in late 2027.1 Those details matter because lyophilized injectables require specialized equipment and process development, while vial handling, capping, washing, and aseptic filling are all part of a tightly controlled manufacturing chain.
Alcami’s Research Triangle Park expansion points to a similar but distinct category of sterile capacity. The company announced GMP readiness of a third sterile fill–finish line at its North Carolina campus, describing it as the fifth sterile fill–finish line qualified for GMP clinical and commercial manufacturing within its drug product manufacturing network.8 Sharp Services announced a $100 million investment across U.S. and European facilities, with U.S. elements that include injectable assembly and packaging capacity in Pennsylvania and sterile filling capacity in Lee, Massachusetts.9 In a separate announcement, Sharp identified a $28 million sterile manufacturing expansion in Lee, including a fourth isolator-based sterile filling line.10
Sterile capacity is also expanding through acquisitions. Thermo Fisher completed the acquisition of Sanofi’s Ridgefield sterile fill–finish and packaging site, and independent reporting described the transaction as involving a sterile fill–finish and packaging facility that Thermo Fisher intended to expand.3,11 ROIS CDMO closed on the acquisition of an injectable drug product manufacturing and packaging site in Phoenix, Arizona, from Bristol Myers Squibb.12 Simtra’s Bloomington strategy includes the purchase of land near its existing facility, with the company describing the acquisition as a step toward expanding U.S. manufacturing capacity for injectable medicines.2
PCI Pharma Services tied its U.S. investment program to both sterile fill–finish and drug–device delivery combination product capabilities. The company announced a major U.S. expansion backed by investments exceeding $1 billion, including infrastructure builds in San Diego, California, and Bedford, New Hampshire, as well as upgrades in Pennsylvania and Illinois.13 That pairing of sterile fill–finish and drug–device capabilities reflects the growing importance of final product presentation, especially for therapies that require particular delivery formats, assembly steps, packaging configurations, or combination-product support.
The range of announcements shows why sterile fill–finish should be treated as a family of specialized capabilities rather than a single bucket. Vial filling, lyophilization, prefilled syringe support, isolator-based sterile manufacturing, injectable packaging, and drug–device assembly each address different client needs. A product requiring lyophilization may not fit the same CDMO profile as a product moving toward a device-enabled presentation. A clinical-stage injectable may need different support than a commercial program requiring validated packaging and long-term supply.
For pharmaceutical customers, this changes the way CDMO capacity should be evaluated. A search for “sterile capacity” may be too broad to identify the right partner. The better questions are more technical: Does the CDMO have the right filling technology? Can it support the required container closure system? Does it have lyophilization capacity and cycle development expertise? Can it handle commercial packaging? Is the line appropriate for the expected batch scale and product presentation? Does the network support both current development needs and later commercial requirements?
Complexity Beyond Sterile Products
The same specialization pattern appears outside sterile drug product manufacturing. Several U.S. expansions focus on product categories that require specific chemistry, formulation, containment, purification, scale-up, or analytical capabilities. These investments may receive less attention than sterile fill–finish projects, but they reveal how CDMOs are positioning themselves around more complex development and commercialization needs.
Veranova’s Devens expansion is directed toward potent compounds, ADC linker–payloads, and other complex molecules. The project includes a 9,000-ft2 addition with a process development laboratory and two cGMP suites.4 ADC-related manufacturing places demands on containment, conjugation chemistry, analytical control, and handling of potent materials. Capacity in this area is not interchangeable with conventional small-molecule infrastructure because the product class brings different risks and technical requirements.
Cambrex’s Waltham expansion reflects another specialized area: peptide API development and manufacturing. The Snapdragon Chemistry facility expansion includes a GMP suite, ISO-7 cleanroom, preparative HPLC chromatography, lyophilization, and storage and increased the facility footprint by 20%.5 Peptide programs can create purification, scale-up, and analytical challenges that differ from those associated with more conventional small molecules. Equipment and expertise therefore become central to the value of the capacity.
Cambrex also announced a $120 million investment in Charles City, Iowa, to expand U.S. API manufacturing. The company described the project as increasing large-scale manufacturing capacity by 40%, approaching nearly one million liters.14 This type of investment fits a different part of the specialization landscape. Rather than focusing on a single modality, it points to the continued importance of domestic API scale, process development, and large-volume manufacturing infrastructure.
Advanced formulation capacity is another prominent thread. Hovione’s East Windsor investment includes a 31,000-ft2 building with two PSD-3 spray dryers for ASDs, with the company describing the project as more than doubling U.S. spray-drying capacity.6 Spray drying is a specialized platform that can be used to address formulation and manufacturability challenges, particularly for compounds that require enabling technologies. Its value lies not only in equipment availability but also in process understanding, formulation design, analytical control, and scale-up experience.
Serán BioScience’s Bend, Oregon, expansion also fits the advanced formulation and complex small-molecule manufacturing pattern. The company announced a 100,000-ft2 commercial manufacturing facility intended to support small molecule therapeutics from first-in-human studies through commercial-scale production, with capabilities tied to complex oral solid dosage (OSD) forms, spray drying, particle engineering, and advanced formulation.15 A later update described the campus as including a 50,000-ft2 manufacturing facility and 50,000 square feet of packaging and supply-chain space.16
Bora Pharmaceuticals’ Maple Grove, Minnesota, announcement adds another example of investment in manufacturing and packaging capabilities. The company announced a multi-year expansion at the former Upsher-Smith site, which Bora acquired in 2024.17 LGM Pharma announced a two-site U.S. manufacturing investment across Rosenberg, Texas, and Colorado Springs, Colorado, bringing the program to $15 million and supporting suppository, semi-solid, and OSD capacity.18
These investments show that specialization is not confined to the newest therapeutic modalities. A poorly soluble small molecule, a peptide requiring complex purification, a potent compound requiring containment, a commercial OSD product with advanced formulation needs, or a dosage form requiring specific manufacturing know-how can all create pressure for more specialized CDMO support. The technical challenges differ, but the strategic logic is similar: sponsors need capacity that matches the product, not merely capacity that is available.
Biologics Drug Substance Remains Part of the U.S. Capacity Picture
Biologics drug substance appeared less frequently in the reviewed announcements than sterile fill–finish, but the examples were substantial. They also show that U.S. CDMO expansion is not limited to drug product operations or small molecule infrastructure.
Bora Biologics opened a $30 million manufacturing expansion in San Diego, adding upstream and downstream GMP processing capabilities for 2,000-L single-use biologics manufacturing. The company described the expansion as including two to four 2,000-L bioreactors, seed trains, and downstream processing equipment.7 This type of capacity addresses a different need from fill–finish or API manufacturing. Biologics drug substance production requires cell culture, purification, process control, and scale-up capabilities that are central to the development and commercialization of protein-based therapies.
Samsung Biologics expanded its U.S. presence through acquisition. The company completed the acquisition of GSK’s Rockville, Maryland, facility, which includes two cGMP manufacturing plants with a combined 60,000 L of drug substance capacity supporting clinical and commercial biologics production.19
The two examples also show different routes to biologics capacity. One involves an expansion of single-use manufacturing capability within an existing CDMO site. The other involves acquisition of a large, established drug substance asset. Both routes can strengthen a CDMO network, but they serve different operational and strategic purposes.
For biologics sponsors, drug substance capacity cannot be separated from broader manufacturing strategy. A program may require upstream and downstream development, analytical support, process characterization, sterile drug product manufacturing, packaging, and long-term supply planning. A CDMO with drug substance capacity may solve one part of that pathway, while another partner or another site in the network may be required for fill–finish or final product presentation. The growth of biologics drug substance capacity therefore reinforces the same broader theme: capacity must be evaluated in relation to the product’s full development and manufacturing path.
Different Paths to Capacity
CDMOs are adding U.S. capacity through multiple models, and the route matters. New construction, major buildouts, site acquisitions, line additions, equipment investments, and network expansions all increase capacity, but they differ in timing, flexibility, risk, and strategic value.
Major buildouts and new infrastructure projects often indicate longer-term commitments to a specific capability area. Piramal’s Lexington expansion adds sterile injectable and lyophilization-related capacity.1 Veranova’s Devens project adds high-potency and ADC-related capabilities.4 Serán’s Bend campus expands commercial small molecule manufacturing, advanced formulation, packaging, and supply chain infrastructure.16 PCI’s U.S. expansion supports sterile fill–finish and drug–device delivery combination products across multiple sites.13 These projects are not interchangeable, but each reflects a deliberate investment in a capability set that requires technical design, capital, quality planning, and specialized staffing.
Acquisition offers another path. Thermo Fisher’s Ridgefield acquisition added a sterile fill–finish and packaging site to its pharma services business.3 Samsung Biologics’ Rockville acquisition added a biologics drug substance facility with 60,000 L of capacity.19 ROIS CDMO’s Phoenix acquisition added an injectable drug product manufacturing and packaging site.12 Acquired sites may bring existing infrastructure, equipment, workforce capabilities, and regulatory history, but their value depends on how well those assets align with CDMO customers and the acquiring company’s network.
Line, suite, and equipment additions represent a more targeted mode of expansion. Alcami’s GMP-ready sterile fill–finish line, Sharp’s fourth isolator-based sterile filling line in Lee, Almac’s GMP-qualified stability chamber expansion in Souderton, and Hovione’s spray dryer addition in East Windsor each expand a defined service lane.6,8,10,20 These investments may be smaller than a new campus, but they can be highly meaningful if they address a specific bottleneck or support a specific class of projects.
Network investments add another dimension. Sharp’s $100 million investment spans U.S. and European facilities, with U.S. additions in sterile filling, injectable assembly and packaging, and OSD packaging and manufacturing.9 Cambrex’s announcements span peptide API capabilities in Waltham and large-scale API manufacturing in Iowa.5,14 LGM’s investment spans two U.S. sites and multiple dosage-form categories.18 In these cases, specialization may be distributed across several facilities rather than concentrated in one site.
For sponsors, the expansion model can influence partner selection. A newly built facility may offer modern design and purpose-built infrastructure but may also involve future qualification timelines. An acquired site may offer established assets and experienced staff, but integration into a CDMO network may shape how quickly and broadly the capacity can serve new customers. A new line or suite may provide more immediate targeted capacity if it is already qualified or near qualification. A network investment may offer flexibility across development, manufacturing, testing, packaging, and commercial supply, but sponsors still need to determine which site performs which function.
What Specialized Capacity Means for (Bio)Pharma Customers
The recent expansion pattern reinforces a practical point for biopharmaceutical companies: CDMO selection is becoming more technical earlier in development. A program’s manufacturing needs may be shaped by solubility, potency, route of administration, container closure requirements, biologics process scale, device strategy, lyophilization needs, analytical requirements, or commercial packaging expectations long before the product reaches late-stage development.
That makes it risky to view outsourcing capacity as a late-stage procurement question. A company developing an injectable product may need to understand early whether the molecule is likely to require lyophilization, what container closure system may be appropriate, whether the final product could move into a prefilled syringe or other device-enabled presentation, and what analytical and stability work will be required to support those choices. The later those questions are addressed, the more difficult it can become to match the product to appropriate capacity.
The same logic applies beyond sterile products. A peptide program may require specialized purification and lyophilization capabilities. A potent compound may require containment and specialized handling. A poorly soluble molecule may require spray drying, particle engineering, or other enabling formulation technologies. A biologic may require a drug substance partner with appropriate upstream and downstream capabilities before a fill–finish strategy can be finalized. A program with unusual dosage-form needs may require a CDMO with experience in suppositories, semi-solids, or specific OSD platforms.
Specialized capacity also affects development continuity. A CDMO that can support early development work may not always have the infrastructure to support later-stage manufacturing or commercial supply. Conversely, a site designed for commercial production may not be the best fit for early formulation exploration or small-batch development work. Sponsors need to evaluate whether the CDMO’s capabilities align with the product’s expected path, including development, scale-up, process validation, regulatory support, and commercial readiness.
The announcements also suggest that sponsors should evaluate the relationship between manufacturing and adjacent services. Almac’s Souderton expansion, for example, focuses on analytical stability capacity rather than manufacturing production.20 That type of investment may be pivotal because stability testing, analytical support, and GMP storage often influence development timelines, regulatory packages, and commercialization planning. Sharp’s and PCI’s announcements similarly show that packaging, assembly, and drug–device capabilities can be central to the manufacturing strategy for certain products.9,13
In this environment, the most useful CDMO evaluation questions are increasingly product-specific. Does the partner have the exact sterile, API, biologics, formulation, packaging, analytical, or device-related capability the program is likely to need? Can that capability support the current stage and the next stage? Is the relevant capacity already qualified, under construction, newly acquired, or planned? Does the CDMO have experience with similar product attributes? Does the network reduce handoffs or create new ones? Those questions are more useful than asking whether a company has “capacity” in the abstract.
What Specialized Capacity Means for CDMOs
For CDMOs, the specialization of capacity raises the bar for differentiation. General expansion may increase available throughput, but specialized expansion can define where a company competes. A CDMO investing in sterile fill–finish, ADC-related manufacturing, peptide APIs, spray drying, biologics drug substance, or drug–device combination capabilities is making a strategic statement about the kinds of programs it wants to attract and support.
That does not mean every CDMO needs to pursue every category. The announcements point instead to more segmented positioning. One company may deepen its sterile injectables network. Another may build around complex small molecules and advanced formulation. Another may use acquisition to add commercial biologics capacity. Another may expand packaging, device assembly, or stability services to support a broader development and commercialization pathway.
This segmentation can be valuable if it gives sponsors a clearer view of technical fit. A CDMO with a strong identity in spray drying, peptide manufacturing, sterile fill–finish, or biologics drug substance may be easier to evaluate for a program with matching needs. At the same time, specialization must be backed by qualified infrastructure, operational experience, quality maturity, and realistic timelines. Announced capacity does not automatically translate into available capacity for every sponsor or every product.
Network strategy becomes important as capabilities become more specialized. A CDMO may be able to support a product through multiple stages if it can connect development, API manufacturing, formulation, drug product manufacturing, analytical testing, packaging, and commercial supply. However, a distributed network also requires coordination. The value of specialization depends on whether the CDMO can make its capabilities work together in a way that reduces friction for customers.
The U.S. expansion activity also shows that smaller investments can have strategic weight. A new stability chamber suite, an additional isolator line, a spray dryer, or a GMP peptide suite may not attract the same attention as a large acquisition or campus expansion, but each can strengthen a CDMO’s position in a defined service area. Specialized capacity is often built through targeted additions as much as through headline-grabbing projects.
The Next Capacity Question Is “What Kind?”
The latest U.S. CDMO expansion announcements show a market in which capacity is becoming more closely linked to product complexity. Sterile fill–finish is the most visible area of investment, but it is not the whole story. ADC-related manufacturing, peptide APIs, large-scale API production, spray drying, complex oral solid dose manufacturing, biologics drug substance, analytical stability capacity, injectable packaging, and drug–device combination products all appear in the broader pattern of expansion.
That matters because the most relevant capacity for a sponsor is rarely generic. The right partner depends on the molecule, dosage form, route of administration, scale, process requirements, regulatory path, presentation, and commercialization plan. A company developing a lyophilized injectable, a peptide, a biologic, an ADC, or a poorly soluble small molecule may face very different outsourcing constraints, even if each program is described broadly as needing development and manufacturing support.
The U.S. CDMO buildout should therefore be understood as a set of targeted capability investments. Some companies are building new infrastructure. Others are acquiring existing sites. Others are adding lines, suites, chambers, dryers, or packaging capabilities. Across those models, the common theme is greater specificity. Capacity is being shaped around what products require.
For sponsors, the implication is straightforward: manufacturing strategy needs to be integrated earlier into development strategy. For CDMOs, the challenge is equally clear: differentiation will depend not only on having capacity, but on having the right capacity, supported by the right expertise, quality systems, and network design. The next phase of CDMO growth will be measured not only in square footage, liters, lines, or investment dollars, but in how well those assets match the products sponsors are trying to bring to patients.
